1. Scrip

Parsabiv Could Allow Amgen To Maintain Control Of Calcimimetics Market

 
• By Michael Cipriano

Amgen's oral calcimimetic Sensipar faces generic competition in 2018, but the new intravenuous Parsabiv has advantages that could make it the more popular alternative.

Lion
Amgen looks set to retain market dominance with Parsabiv • Source: Shutterstock

With superior efficacy, a lower rate of adverse events and a potential adherence benefit, Amgen Inc. is hoping the US FDA's approval of its secondary hyperparathyroidism treatment Parsabiv (etelcalcetide)‎ will strengthen its hold on the calcimimetics market as the company prepares to face generic competition for Sensipar (cinacalcet).

Parsabiv – approved Feb. 8 for the treatment of secondary hyperparathyroidism in adults with chronic kidney disease on hemodialysis – is the first intravenuous calcimimetic backed by the agency

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Drug Pricing

More from Scrip

Sarepta Slammed By Double Blow: Elevidys Sales Miss, Prasad’s CBER Appointment

 
• By Mandy Jackson

Sarepta’s stock price was battered after Vinay Prasad was appointed to lead the US FDA’s CBER, then the company’s shares were bruised when Q1 Elevidys sales came in below consensus.

Marea Eyes Cardioprotective Benefit With ANGPTL4 Inhibition

 
• By Joseph Haas

Phase IIa data for ANGPTL4-targeted antibody shows reduced triglycerides and remnant cholesterol, which Marea asserts indicates potential to protect against cardiovascular outcomes.

BeiGene To Trade Beach For Chalet In Swiss Redomiciling As BeOne

 
• By Alaric DeArment

The biotech saw a slight quarter-over-quarter decline in sales from the BTK inhibitor Brukinsa, which it attributed to seasonality, while revenues overall missed some analyst estimates.